Philips has secured a significant victory in one of the disputes arising from the Respironics sleep-apnea device recall. On 10 October, the Enterprise Chamber of the Amsterdam Court of Appeal rejected requests by investor association VEB and a large group of shareholders for an inquiry into the company's management and disclosures. The judgment matters because it assesses whether the evidence justified a formal investigation into governance at the Dutch parent. It is not a general judicial finding that the recalled devices were safe or that every claim arising from the episode has been resolved.
What the judges actually decided
In its published explanation, the court said it had reviewed extensive internal material and found no sufficient grounds to doubt Philips' policy or conduct in a way that warranted an inquiry. It found no indication that the management and supervisory boards received reliable information about potential health risks materially earlier than disclosed. According to the court, sufficiently reliable research evidence about the PE-PUR foam risk emerged in the first months of 2021. The judges also rejected the argument that Philips should necessarily have intervened earlier at its US Respironics subsidiary or that its public communications were misleading. Crucially, the court expressly said it was not deciding whether Respironics itself had made mistakes or whether Philips was liable for investor losses.
An inquiry and a liability claim answer different questions
An Enterprise Chamber inquiry is a governance mechanism. Applicants must show well-founded reasons to doubt management policy or conduct before the court orders a deeper investigation. That threshold differs from tests in product-liability, consumer, regulatory or securities claims. Reuters reported that the 2021 recall affected roughly 15 million devices and that Philips agreed in 2024 to pay $1.1 billion to settle US personal-injury claims. Those facts illustrate the scale of the episode but do not contradict the Dutch court's narrower conclusion. For investors, the ruling removes one potential channel of governance uncertainty. It does not reverse past cash outflows, restore reputation or determine other proceedings. The more useful lens is whether current control systems and operating performance support recovery.
Read the next results alongside the ruling
The immediate legal question is whether applicants pursue any available procedural response and whether separate proceedings generate new findings. The commercial questions concern product-quality systems, remediation costs, litigation provisions, Respironics performance and customer confidence. Investors should read Philips' next results and legal-risk disclosures alongside the court's explanation, not substitute one for the other. The Enterprise Chamber declined to investigate the parent company's governance on the evidence presented. That is a meaningful outcome, but treating it as full exoneration would go further than the judges themselves did.
How to use this analysis
Company reporting needs a consistent bridge from operating activity to accounting results. Orders, deliveries, revenue, profit and cash can belong to different periods. Group figures can also cover operations far beyond the place attached to the story, so local economic claims require a separate location-specific source.
Source and verification note
The reporting base for this article is Amsterdam Court of Appeal: Philips decision, 10 October and Reuters: Philips shareholder ruling, 10 October. The link is provided to the source page or release so readers can check the reporting period, definitions and later revisions. Figures are not extended beyond the source's geographic or institutional scope, and forecasts remain labelled as expectations until an official release records the outcome.